Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EMA revokes eight class waivers for PIPs to 'encourage' development of drugs for children

This article was originally published in SRA

Executive Summary

The European Medicines Agency has revoked eight class waivers for pediatric investigation plans (PIPs) in a bid to encourage companies to develop more new medicines for use in children. The agency has also confirmed nine class waivers on its current list of class waivers, which means there continues to be no requirement for PIPs for medicines for treating these diseases, and it has updated 15 class waivers on the list1-5.

You may also be interested in...

EMA's Revised Pediatric Class Waiver List Comes Into Effect July 28

Marketing authorization applications for medicines that are no longer subject to a class waiver as per the revised list will need a pediatric investigation plan.

Pediatric Study Requirements For Cancer Have FDA Support, But Pose Industry Challenges

Biosimilars could face new requirements if RACE for Children Act expands PREA to molecularly targeted cancer drugs approved for adult indications; other stakeholders also worry about general feasibility.

Global Medtech Guidance Tracker: May 2023

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Forty-seven documents have been posted on the tracker since its last update.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts